Daniel Heng
Overview
Explore the profile of Daniel Heng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
205
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, et al.
Nat Cancer
. 2025 Jan;
6(2):372-384.
PMID: 39789182
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell...
2.
Robert A, Mallick R, McIsaac D, Lavallee L, Bhindi B, Heng D, et al.
J Urol
. 2024 Dec;
213(4):455-466.
PMID: 39622017
Purpose: Postoperative prognostic tools allow for improved prediction of future recurrence risk, patient counseling, assessment of eligibility for adjuvant treatments, and appropriate follow-up surveillance. The purpose of this analysis was...
3.
Barragan-Carrillo R, Saad E, Saliby R, Sun M, Albiges L, Bex A, et al.
Eur Urol
. 2024 Nov;
87(2):143-154.
PMID: 39505582
Background And Objective: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide...
4.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, El Zarif T, McClure H, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102230.
PMID: 39461026
Background: Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for metastatic castration-resistant prostate cancer (mCRPC), and docetaxel (D) is reserved as...
5.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, et al.
Clin Genitourin Cancer
. 2024 Aug;
22(5):102185.
PMID: 39217072
Background: Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical practice, most mCRPC still derive from...
6.
Graham J, Ghosh S, Breau R, Wood L, Tanguay S, Bosse D, et al.
Clin Genitourin Cancer
. 2024 Mar;
22(3):102060.
PMID: 38521648
Background: Cabozantinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated efficacy in metastatic renal cell carcinoma (mRCC). The association between toxicity and therapeutic effectiveness has been established with other...
7.
Cardenas L, Ghosh S, Finelli A, Wood L, Kollmannsberger C, Basappa N, et al.
JCO Glob Oncol
. 2023 Nov;
9:e2300271.
PMID: 37992270
Purpose: Standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have greatly evolved. However, the availability of emerging options in global health care systems can vary. We sought to describe the...
8.
Heer E, Ruan Y, Boyne D, Jarada T, Heng D, Henning J, et al.
CMAJ
. 2023 Jun;
195(23):E804-E812.
PMID: 37308211
Background: The COVID-19 pandemic is suspected to have affected cancer care and outcomes among patients in Canada. In this study, we evaluated the impact of the state of emergency period...
9.
Millan B, Breau R, Mallick R, Wood L, Rendon R, Finelli A, et al.
Urol Oncol
. 2023 May;
41(7):328.e15-328.e23.
PMID: 37202328
Purpose: To compare characteristics and outcomes of patients included versus those not in adjuvant therapy trials post complete resection of renal cell carcinoma (RCC). Methods: Adult patients following complete resection...
10.
Shayeb A, McManus H, Urman D, Jani C, Zhang T, Dizman N, et al.
Clin Genitourin Cancer
. 2022 Nov;
21(1):55-62.
PMID: 36411184
Background: In patients with renal cell carcinoma (RCC) on cabozantinib, venous thromboembolism (VTE) management remains challenging due to limited safety data regarding direct oral anticoagulants (DOACs) use in conjunction with...